{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:07:21Z","timestamp":1789524441369,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82320108015, 81972596, 81772963"],"award-info":[{"award-number":["82320108015, 81972596, 81772963"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102709"],"award-info":[{"award-number":["82102709"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Science and Technology Program key projects","doi-asserted-by":"publisher","award":["2023B01J1004"],"award-info":[{"award-number":["2023B01J1004"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Science and Technology Program key projects","doi-asserted-by":"publisher","award":["SL2024A04J02224"],"award-info":[{"award-number":["SL2024A04J02224"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Concurrent chemotherapy is the standard treatment strategy for advanced-stage nasopharyngeal carcinoma (NPC). However, chemoresistance inevitable develops and the underlying mechanism remains poorly understood. In this study, we identify the arginine methyltransferase PRMT5 as a key gene associated with chemoresistance to paclitaxel in NPC. We demonstrate that PRMT5 facilitated paclitaxel resistance by inducing KCNMB4 expression in nasopharyngeal carcinoma cells. Mechanistically, PRMT5 is recruited to the promoter region of KCNMB4, where it catalyzes H3R2me2s and enhances KCNMB4 expression. Furthermore, elevated levels of PRMT5 or KCNMB4 correlated with poorer survival and higher recurrence rates in NPC patients. Notably, genetic or pharmacological inhibition of PRMT5 significantly sensitized NPC cells to paclitaxel, both in vitro and in vivo. Collectively, these results suggest that the PRMT5-KCNMB4 axis plays a crucial role in mediating chemoresistance in NPC and targeting this axis may provide a promising therapeutic strategy for late-stage NPC patients.<\/jats:p>","DOI":"10.1038\/s41419-025-08190-y","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:41:54Z","timestamp":1767969714000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PRMT5 upregulates KCNMB4 expression via histone methylation to promote paclitaxel resistance in advanced nasopharyngeal carcinoma"],"prefix":"10.1038","volume":"17","author":[{"given":"Lizhen","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sailan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peili","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guixiang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Han","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoyu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JianFeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9035-6814","authenticated-orcid":false,"given":"Hai-Qiang","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4605-4624","authenticated-orcid":false,"given":"Jing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"8190_CR1","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S0140-6736(23)00269-6","volume":"401","author":"R You","year":"2023","unstructured":"You R, Liu YP, Xie YL, Lin C, Duan CY, Chen DP, et al. Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2023;401:917\u201327.","journal-title":"Lancet"},{"key":"8190_CR2","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1001\/jamaoncol.2024.2519","volume":"10","author":"P Bayatfard","year":"2024","unstructured":"Bayatfard P, Sari SY, Yazici G. Chemotherapy, Radiation Therapy, and Nasopharyngeal Carcinoma. Jama Oncol. 2024;10:1292.","journal-title":"Jama Oncol"},{"key":"8190_CR3","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1001\/jamaoncol.2022.0122","volume":"8","author":"WZ Li","year":"2022","unstructured":"Li WZ, Lv X, Hu D, Lv SH, Liu GY, Liang H, et al. Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma A Multicenter Phase 3 Randomized Clinical Trial. Jama Oncol. 2022;8:706\u201314.","journal-title":"Jama Oncol"},{"key":"8190_CR4","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1001\/jamaoncol.2022.4656","volume":"8","author":"JJ Miao","year":"2022","unstructured":"Miao JJ, Wang L, Tan SH, Li JG, Yi JL, Ong EHW, et al. Adjuvant Capecitabine Following Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma A Randomized Clinical Trial. Jama Oncol. 2022;8:1776\u201385.","journal-title":"Jama Oncol"},{"key":"8190_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molcel.2008.12.013","volume":"33","author":"MT Bedford","year":"2009","unstructured":"Bedford MT, Clarke SG. Protein Arginine Methylation in Mammals: Who, What, and Why. Mol Cell. 2009;33:1\u201313.","journal-title":"Mol Cell"},{"key":"8190_CR6","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41573-021-00159-8","volume":"20","author":"Q Wu","year":"2021","unstructured":"Wu Q, Schapira M, Arrowsmith CH, Barsyte-Lovejoy D. Protein arginine methylation: from enigmatic functions to therapeutic targeting. Nat Rev Drug Discov. 2021;20:509\u201330.","journal-title":"Nat Rev Drug Discov"},{"key":"8190_CR7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/mrd.22024","volume":"79","author":"E Blackwell","year":"2012","unstructured":"Blackwell E, Ceman S. Arginine methylation of RNA-binding proteins regulates cell function and differentiation. Mol Reprod Dev. 2012;79:163\u201375.","journal-title":"Mol Reprod Dev"},{"key":"8190_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.molcel.2016.11.003","volume":"65","author":"RS Blanc","year":"2017","unstructured":"Blanc RS, Richard S. Arginine Methylation: The Coming of Age. Mol Cell. 2017;65:8\u201324.","journal-title":"Mol Cell"},{"key":"8190_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0092-8674(01)00423-8","volume":"106","author":"AE McBride","year":"2001","unstructured":"McBride AE, Silver PA. State of the Arg: Protein methylation at arginine comes of age. Cell. 2001;106:5\u20138.","journal-title":"Cell"},{"key":"8190_CR10","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/ni.2873","volume":"15","author":"KA Mowen","year":"2014","unstructured":"Mowen KA, David M. Unconventional post-translational modifications in immunological signaling. Nat Immunol. 2014;15:512\u201320.","journal-title":"Nat Immunol"},{"key":"8190_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/onc.2016.205","volume":"36","author":"H Chen","year":"2017","unstructured":"Chen H, Lorton B, Gupta V, Shechter D. A TGF\u03b2-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression. Oncogene. 2017;36:373\u201386.","journal-title":"Oncogene"},{"key":"8190_CR12","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.tibs.2011.09.001","volume":"36","author":"V Karkhanis","year":"2011","unstructured":"Karkhanis V, Hu YJ, Baiocchi RA, Imbalzano AN, Sif S. Versatility of PRMT5-induced methylation in growth control and development. Trends Biochem Sci. 2011;36:633\u201341.","journal-title":"Trends Biochem Sci"},{"key":"8190_CR13","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1038\/sj.emboj.7601794","volume":"26","author":"S Pal","year":"2007","unstructured":"Pal S, Baiocchi RA, Byrd JC, Grever MR, Jacob ST, Sif S. Low levels of miR-92b\/96 induce PRMT5 translation and H3R8\/H4R3 methylation in mantle cell lymphoma. Embo J. 2007;26:3558\u201369.","journal-title":"Embo J"},{"key":"8190_CR14","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.1016\/j.celrep.2017.11.096","volume":"21","author":"K Chiang","year":"2017","unstructured":"Chiang K, Zielinska AE, Shaaban AM, Sanchez-Bailon MP, Jarrold J, Clarke TL, et al. PRMT5 Is a Critical Regulator of Breast Cancer Stem Cell Function via Histone Methylation and FOXP1 Expression. Cell Rep. 2017;21:3498\u2013513.","journal-title":"Cell Rep"},{"key":"8190_CR15","doi-asserted-by":"publisher","first-page":"9644","DOI":"10.1073\/pnas.2005945117","volume":"117","author":"S AbuHammad","year":"2020","unstructured":"AbuHammad S, Cullinane C, Martin C, Bacolas Z, Ward T, Chen HQ, et al. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4\/6 inhibitors in melanoma. Proc Natl Acad Sci USA. 2020;117:9644\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8190_CR16","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10549-017-4597-6","volume":"168","author":"Z Wang","year":"2018","unstructured":"Wang Z, Kong J, Wu Y, Zhang JL, Wang T, Li NL, et al. PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer. Breast Cancer Res Tr. 2018;168:531\u201342.","journal-title":"Breast Cancer Res Tr"},{"key":"8190_CR17","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.3892\/or.2015.4513","volume":"35","author":"DK Yang","year":"2016","unstructured":"Yang DK, Liang TS, Gu Y, Zhao YL, Shi YG, Zuo XX, et al. Protein N-arginine methyltransferase 5 promotes the tumor progression and radioresistance of nasopharyngeal carcinoma. Oncol Rep. 2016;35:1703\u201310.","journal-title":"Oncol Rep"},{"key":"8190_CR18","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/bs.irn.2016.04.001","volume":"128","author":"C Contet","year":"2016","unstructured":"Contet C, Goulding SP, Kuljis DA, Barth AL. BK Channels in the Central Nervous System. Int Rev Neurobiol. 2016;128:281\u2013342.","journal-title":"Int Rev Neurobiol"},{"key":"8190_CR19","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/nrn1992","volume":"7","author":"L Salkoff","year":"2006","unstructured":"Salkoff L, Butler A, Ferreira G, Santi C, Wei A. High-conductance potassium channels of the SLO family. Nat Rev Neurosci. 2006;7:921\u201331.","journal-title":"Nat Rev Neurosci"},{"key":"8190_CR20","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1016\/j.bbamem.2014.12.016","volume":"1848","author":"E Lastraioli","year":"2015","unstructured":"Lastraioli E, Iorio J, Arcangeli A. Ion channel expression as promising cancer biomarker. Bba-Biomembranes. 2015;1848:2685\u2013702.","journal-title":"Bba-Biomembranes"},{"key":"8190_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/nrc3635","volume":"14","author":"LA Pardo","year":"2014","unstructured":"Pardo LA, St\u00fchmer W. The roles of K+ channels in cancer. Nat Rev Cancer. 2014;14:39\u201348.","journal-title":"Nat Rev Cancer"},{"key":"8190_CR22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/00001756-200203250-00008","volume":"13","author":"D Basrai","year":"2002","unstructured":"Basrai D, Kraft R, Bollensdorff C, Liebmann L, Benndorf K, Patt S. BK channel blockers inhibit potassium-induced proliferation of human astrocytoma cells. Neuroreport. 2002;13:403\u20137.","journal-title":"Neuroreport"},{"key":"8190_CR23","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1038\/sj.onc.1210036","volume":"26","author":"M Bloch","year":"2007","unstructured":"Bloch M, Ousingsawat J, Simon R, Schraml P, Gasser TC, Mihatsch MJ, et al. KCNMA1 gene amplification promotes tumor cell proliferation in human prostate cancer. Oncogene. 2007;26:2525\u201334.","journal-title":"Oncogene"},{"key":"8190_CR24","first-page":"169s","volume":"69","author":"D Khaitan","year":"2009","unstructured":"Khaitan D, Sankpal UT, Ningaraj NS. Role of KCNMA1 gene in breast cancer invasion and metastasis to brain. Cancer Res. 2009;69:169s\u2013169s.","journal-title":"Cancer Res"},{"key":"8190_CR25","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1007\/s10495-007-0101-9","volume":"12","author":"XB Han","year":"2007","unstructured":"Han XB, Wang F, Yao WX, Xing H, Weng DH, Song XH, et al. Heat shock proteins and p53 play a critical role in K channel-mediated tumor cell proliferation and apoptosis. Apoptosis. 2007;12:1837\u201346.","journal-title":"Apoptosis"},{"key":"8190_CR26","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1523\/JNEUROSCI.22-05-01840.2002","volume":"22","author":"XJ Liu","year":"2002","unstructured":"Liu XJ, Chang YC, Reinhart PH, Sontheimer H. Cloning and characterization of glioma BK, a novel BK channel isoform highly expressed in human glioma cells. J Neurosci. 2002;22:1840\u20139.","journal-title":"J Neurosci"},{"key":"8190_CR27","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1002\/jcp.25592","volume":"232","author":"P Rosa","year":"2017","unstructured":"Rosa P, Sforna L, Carlomagno S, Mangino G, Miscusi M, Pessia M, et al. Overexpression of Large-Conductance Calcium-Activated Potassium Channels in Human Glioblastoma Stem-Like Cells and Their Role in Cell Migration. J Cell Physiol. 2017;232:2478\u201388.","journal-title":"J Cell Physiol"},{"key":"8190_CR28","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1111\/bph.15147","volume":"179","author":"CJ Mohr","year":"2022","unstructured":"Mohr CJ, Schroth W, M\u00fcrdter TE, Gross D, Maier S, Stegen B, et al. Subunits of BK channels promote breast cancer development and modulate responses to endocrine treatment in preclinical models. Brit J Pharm. 2022;179:2906\u201324.","journal-title":"Brit J Pharm"},{"key":"8190_CR29","doi-asserted-by":"publisher","first-page":"5562","DOI":"10.1073\/pnas.100118597","volume":"97","author":"P Meera","year":"2000","unstructured":"Meera P, Wallner M, Toro L. A neuronal \u03b2 subunit (KCNMB4) makes the large conductance, voltage- and Ca-activated K channel resistant to chavybdotoxin and iberiotoxin. Proc Natl Acad Sci USA. 2000;97:5562\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8190_CR30","doi-asserted-by":"publisher","first-page":"6866","DOI":"10.1002\/jcp.26448","volume":"233","author":"P Rosa","year":"2018","unstructured":"Rosa P, Catacuzzeno L, Sforna L, Mangino G, Carlomagno S, Mincione G, et al. BK channels blockage inhibits hypoxia-induced migration and chemoresistance to cisplatin in human glioblastoma cells. J Cell Physiol. 2018;233:6866\u201377.","journal-title":"J Cell Physiol"},{"key":"8190_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06028-z","volume":"14","author":"L Liu","year":"2023","unstructured":"Liu L, Deng P, Liu S, Hong JH, Xiao R, Guan P, et al. Enhancer remodeling activates NOTCH3 signaling to confer chemoresistance in advanced nasopharyngeal carcinoma. Cell Death Dis. 2023;14:513.","journal-title":"Cell Death Dis"},{"key":"8190_CR32","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/nsmb.2209","volume":"19","author":"V Migliori","year":"2012","unstructured":"Migliori V, M\u00fcller J, Phalke S, Low D, Bezzi M, Mok WC, et al. Symmetric dimethylation of H3R2 is a newly identified histone mark that supports euchromatin maintenance. Nat Struct Mol Biol. 2012;19:136\u201344.","journal-title":"Nat Struct Mol Biol"},{"key":"8190_CR33","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1158\/0008-5472.CAN-20-2125","volume":"81","author":"LZ Liu","year":"2021","unstructured":"Liu LZ, Liu SL, Deng P, Liang YJ, Xiao R, Tang LQ, et al. Targeting the IRAK1-S100A9 Axis Overcomes Resistance to Paclitaxel in Nasopharyngeal Carcinoma. Cancer Res. 2021;81:1413\u201325.","journal-title":"Cancer Res"},{"key":"8190_CR34","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","volume":"17","author":"Y Sun","year":"2016","unstructured":"Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17:1509\u201320.","journal-title":"Lancet Oncol"},{"key":"8190_CR35","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1158\/1078-0432.CCR-23-0092","volume":"29","author":"M Vieito","year":"2023","unstructured":"Vieito M, Moreno V, Spreafico A, Brana I, Wang JS, Preis M, et al. Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in advanced solid tumors. Clin Carcer Res. 2023;29:3592\u2013602.","journal-title":"Clin Carcer Res"},{"key":"8190_CR36","doi-asserted-by":"publisher","first-page":"58","DOI":"10.36401\/JIPO-22-1","volume":"5","author":"K Feustel","year":"2022","unstructured":"Feustel K, Falchook GS. Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review. J Immunother Precis. 2022;5:58\u201367.","journal-title":"J Immunother Precis"},{"key":"8190_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11060-019-03274-0","volume":"145","author":"B Holmes","year":"2019","unstructured":"Holmes B, Benavides-Serrato A, Saunders JT, Landon KA, Schreck AJ, Nishimura RN, et al. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma. J Neuro-Oncol. 2019;145:11\u201322.","journal-title":"J Neuro-Oncol"},{"key":"8190_CR38","doi-asserted-by":"publisher","first-page":"28068","DOI":"10.1073\/pnas.2009899117","volume":"117","author":"XL Wei","year":"2020","unstructured":"Wei XL, Yang JK, Adair SJ, Ozturk H, Kuscu C, Lee KY, et al. Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells. P Natl Acad Sci USA. 2020;117:28068\u201379.","journal-title":"P Natl Acad Sci USA"},{"key":"8190_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215594","volume":"532","author":"X Yang","year":"2022","unstructured":"Yang X, Zeng Z, Jie X, Wang Y, Han J, Zheng Z, et al. Arginine methyltransferase PRMT5 methylates and destabilizes Mxi1 to confer radioresistance in non-small cell lung cancer. Cancer Lett. 2022;532:215594.","journal-title":"Cancer Lett"},{"key":"8190_CR40","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1016\/j.chembiol.2024.08.003","volume":"31","author":"K Zhang","year":"2024","unstructured":"Zhang K, Wei J, Zhang S, Fei L, Guo L, Liu X, et al. A chemical screen identifies PRMT5 as a therapeutic vulnerability for paclitaxel-resistant triple-negative breast cancer. Cell Chem Biol. 2024;31:1942\u201357 e1946.","journal-title":"Cell Chem Biol"},{"key":"8190_CR41","doi-asserted-by":"publisher","first-page":"16742","DOI":"10.1182\/blood-2024-203060","volume":"144","author":"TM Kim","year":"2024","unstructured":"Kim TM, Lewis KL, Alderuccio JP, Lee HJ, Derenzini E, Zinzani PL, et al. PRIMAVERA: A Modular Phase I\/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed\/Refractory Hematologic Malignancies. Blood. 2024;144:16742\u20133.","journal-title":"Blood"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08190-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08190-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08190-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T21:05:31Z","timestamp":1768165531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08190-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8190"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08190-y","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"19 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal care and experimental procedures were approved by the Ethics of Animal Experiments of Guangdong People\u2019s Hospital. For human samples, written informed consent was obtained from each patient who provided the tissue. Procedures, information and consent forms were approved by the Institutional Ethical Review Board of Guangdong Provincial People\u2019s Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"19"}}